

Rehabilitation for chronic neurological disorders (including acquired brain injury) Meeting 4

Date: 10th June 2022

Location Via Zoom

Minutes: Confirmed

Committee members present:						
Ian Bernstein	Present for items 1 – 6					
Rachel Keetley	Present for items 1 – 6					
Emer McGilloway	Present for items 4 – 6					
Parashar Ramanuj	Present for items 3 - 6					
Jane Williams	Present for items 1 - 6					
Nicholas Behn	Present for items 1 – 6					
Lisa Bunn	Present for items 1 - 6					
Teresa Clark	Present for items 1 – 6					
Jenny Jim	Present for items 1 – 5					
Jacqueline Dean	Present for items 1- 6					
Jill Kings	Present for items 1 – 6					
Rachel Farrell	Present for items 1 – 6					
Gaby Parker	Present for items 4 – 6					
Joanne Powell	Present for items 1 – 6					
Geraldine (Gerry) Roxburgh	Present for items 1 – 6					

In attendance:		
Lisa Boardman	Guideline Lead	Present for items 1 – 6
Hayley Shaw	Project Manager	Present for items 1 – 3
Jen M Francis	Senior Systematic Reviewer	Present for items 1 – 6
Alice Navein	Systematic Reviewer	Present for items 1 – 6
Ted Barker	Systematic Reviewer	Present for items 1 – 6
Eric Slade	Senior Health Economist	Present for items 1 – 6
Timothy Reeves	Information Scientist	Present for items 1 – 6
Charlie Fairhurst	Clinical Advisor	Present for items 1 – 6

Apologies:	
Yvonne Pettigrew	Lay Member
Clifford Middleton	Guideline Commissioning Manager

1. Welcome and objectives of the meeting

The Chair welcomed the committee members and attendees to the 4th Guideline Committee meeting on Rehabilitation for chronic neurological disorders (including acquired brain injury).

The Chair informed the committee that apologies had been received as noted above.

The Chair outlined the objectives of the meeting and the meeting etiquette.

2. Confirmation of matter under discussion and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was rehabilitation for chronic neurological disorders (including acquired brain injury). The Chair asked everyone to verbally declare any interests that have risen since the last meeting. New interests were declared and noted below:

Name	Role	Type of interest	Description of interest	Releva	nt dates		Comments
				Interest arose	Interest declared	Interest ceased	-
Dr Ian Bernstein	Chair	Direct - non-financial professional and personal interests	I co-presented a webinar "Managing Low Back Pain and Sciatica", based on NICE NG59 to the Primary Care Rheumatology & Musculoskeletal Medicine (PCRMM) Society. The core slides have previously been approved by NICE as I was a committee member. I have not claimed any expenses or honoraria	31.05. 2022	10.06.20	31.05.2022	
Mrs Rachel Keetley	Topic Advisor	Direct - non- financial professional and personal interests	University of Nottingham School of Medicine Sue Watson presentation (PhD student presentations) — presentation of PhD results so far	17.05. 2022	21.06.20	17.05.2022	

			(long term needs of CYP with ABI)				
Mrs Rachel Keetley	Topic Advisor	Direct - non- financial professional and personal interests	European Academy of Childhood Disability Conference – virtual poster presentations of PhD protocol and survey results	18.05. 2022	21.06.20	20.05.2022	
Mrs Rachel Keetley	Topic Advisor	Direct - non- financial professional and personal interests	University of Nottingham School of Medicine Centre for Rehabilitation and Ageing Research PhD Student seminar — presentation of PhD results so far (long term needs of CYP with ABI)	01.06. 2022	21.06.20	01.06.2022	
Mrs Rachel Keetley	Topic Advisor	Direct - non- financial professional and personal interests	Nottingham University Hospitals EEE Conference – presentation of PhD results so far (long term needs of CYP with ABI)	09.06. 2022	21.06.20	09.06.2022	
Dr Rachel Farrell	Committee member	Direct – financial interests	New role as Consultant on the Neuro- rehabilitation Unit Cleveland Clinic London (private practice)	1 st April 2022	10.06.20 22	Ongoing	
Dr Rachel Farrell	Committee member	Direct - non- financial professional and personal interests	Part of executive committee creating a "Spasticity academy" with the support of the Neurology Academy. This will be a hybrid online and face to face education resource with the aim to develop a programme of	May 2022	10.06.20	Ongoing	

			T	Г		ı	ı	1
				talks and case				
				based sessions to				
				review the				
				literature around				
				spasticity and best				
				clinical practice /				
				service delivery.				
				The initial				
				programme is to				
				be prepared by				
				October 2022				
-	Dr Rachel	Committee	Direct - non-	Applied to be the	June	10.06.20	Ongoing	
	Farrell	member	financial	clinical lead on an	2022	22	0.180.1.8	
			professional	NHSE policy	LULL			
			and	proposal to				
			personal	provide Prolonged				
			interests	Release				
			interests	Fampridine to				
				people with				
				Multiple Sclerosis				
				and walking				
				difficulties in				
				England. NICE have				
				not deemed cost				
				effective at the list				
				price, however the				
				company will agree				
				a confidential				
				discount and thus				
				a PPP via NHSE				
				recommended.				
				The treatment was				
				considered in the				
				MS clinical				
				guideline and not				
				yet published				
	Dr Rachel	Committee	Direct - non-	Medical Advisor to	March	10.06.20	Ongoing	
	Farrell	member	financial	the MS society. I	2019	22		
			professional	provide medical				
			and	opinion to the MS				
			personal	society regarding				
			interests	new treatments,				
				interventions for				
				people with MS to				
				help them develop				
				their statements				
				regarding policy				
				and information /				
				guidance for				
				people with MS.				
				For example				
ш		<u> </u>	l	F	L	<u> </u>	l	I

throughout the pandemic I contributed to the advice regarding risk to people with MS if they contracted COVID, shielding guidance, DMTs and Covid, vaccination etc. MS Committee Teresa member of financial professional and personal interests contracture management (particularly relating to the use of botulinum toxin, medicines, splints and serial casts). No one drug company is ever advocated for pharmacological treatments are discussed 16 generically. I do not privately receive payment for these, my employer receives payment for the payment for			T .		1		ı	1
contributed to the advice regarding risk to people with MS if they contracted COVID, shielding guidance, DMTs and Covid, vaccination etc. Ms Teresa Cark Committee Teresa Clark Cla								
advice regarding risk to people with MS if they contracted COVID, shielding guidance, DMTs and Covid, vaccination etc. Ms Committee Teresa Clark Clar				pandemic I				
risk to people with MS if they contracted COVID, shielding guidance, DMTs and Covid, secretary contracted COVID, shielding guidance, DMTs and Covid, secretary contracted member Clark Ms Committee Teresa Clark Inationally and nationally and personal spasticity and committee the topic of personal spasticity and committee the management (particularly relating to the use of botulinum toxin, medicines, splints and serial casts). No one drug company is ever advocated for — pharmacological treatments are discussed 16-generically. In the course overse payment for these, my employer receives payment for these, my employer receives the available evidence base and practical casts. It doesn't advocate for any one intervention over the other, or even over no intervention (as the evidence doesn't promote a stance either way), rather it discusses (Polan di Company (Po				contributed to the				
MS if they contracted COVID, shielding guidance, DMTs and Covid, vaccination etc. Iroutinely teach nationally and professional and personal interests Interests Iroutinely teach nationally and dates the topic of spasticity and contracture management (particularly relating to the use of botulinum toxin, medicines, splints and serial casts). No one drug company is ever advocated for 22 pharmacological treatments are discussed 16-generically. Id on ort privately receive payment for these, my employer receives payment. The course covers the available evidence base and practical fabrication of serial casts. It doesn't advocate for any one intervention over the other, or even over no intervention (as the evidence a stance either way). If a contracting the provided a stance either way). Intervention cas the evidence a stance either way). Intervention cas the fee by the payment of the provided a stance either way). Intervention cas the revidence a stance either way).				advice regarding				
Committee Teresa member Clark MS Committee Teresa member Clark Direct-non-financial professional and personal interests Interests Direct-non-financial professional and personal internationally and internationally and internationally and internationally on dates since sinc				risk to people with				
Shielding guidance, DMTs and Covid, vaccination etc. Ms Committee Teresa (Clark Clark Cla				MS if they				
Ms Committee Teresa Clark				contracted COVID,				
Ms Committee Teresa (Clark Clark Cla				shielding guidance,				
Ms Teresa Committee member financial professional financial professional and personal internationally on the topic of spasticity and contracture management (particularly relating to the use of botulinum toxin, medicines, splints and serial casts). No one drug company is ever advocated for pharmacological treatments are discussed 16-generically. I do not privately receive payment for these, my employer receives payment. The course covers the available evidence base and practical particularly advocate for any one intervention over the other, or even over no intervention (as tance either way), rather it discusses feel				DMTs and Covid,				
Ms Teresa Clark Committee member financial professional financial professional and personal internationally on the topic of spasticity and contracture management (particularly relating to the use of botulinum toxin, medicines, splints and serial casts). No one drug company is ever advocated for pharmacological treatments are discussed 16-generically. I do not privately receive payment for these, my employer receives payment. The course covers the available evidence base and practical 21-fabrication of serial casts. It doesn't advocate for any one intervention over the other, or even over no intervention (as the evidence das stance either way), rather it discusses feel				vaccination etc.				
Teresa Clark member financial professional and professional and the topic of spasticity and contracture management (particularly relating to the use of bottlinum toxin, medicines, splints and serial casts). No one drug company is ever advocated for pharmacological treatments are discussed 16-generically. I do not privately receive payment for these, my employer receives payment. The course covers the available evidence base and practical casts. It doesn't advocate for any one intervention over the other, or even over no intervention is atance either way), rather it discusses I feb.	Ms	Committee	Direct - non-	I routinely teach	Teachi	20.06.20	Ongoing	
Clark professional and the topic of spasticity and interests of botulinum toxin, medicines, splints and serial casts). No one drug company is ever advocated for pharmacological treatments are discussed generically. Ido not privately receive payment for these, my employer receives payment. The course covers the available evidence base and practical fabrication of serial casts. It doesn't advocate for any one intervention over the other, or even over no intervention intervention (as the evidence das stance either way), rather it discusses space intervention designed and practical stance either way), rather it discusses space intervention designed and practical casts. It doesn't advocate for any one intervention (as the evidence as stance either way), rather it discusses (Polan explanation of serial stance either way), rather it discusses (Polan explanation of serial stance either way), rather it discusses (Polan explanation of serial stance either way), rather it discusses (Polan explanation of serial stance either way), rather it discusses (Polan explanation of serial stance either way), rather it discusses (Polan explanation of serial stance either way), rather it discusses (Polan explanation of serial stance either way), rather it discusses (Polan explanation of serial stance either way), rather it discusses (Polan explanation of serial stance either way), rather it discusses (Polan explanation of serial stance either way), rather it discusses (Polan explanation of serial stance either way).	Teresa	member	financial	nationally and	ng	22		
and personal interests spasticity and commit interests spasticity and commit contracture ttee management (particularly relating to the use of botulinum toxin, medicines, splints and serial casts). No one drug company is ever advocated for — pharmacological treatments are discussed generically. I 8/5/2 I do not privately receive payment for these, my employer receives payment. The course covers the available evidence base and practical fabrication of serial casts. It doesn't advocate for any one intervention over the other, or even over no intervention (as the evidence doesn't promote a stance either way), rather it discusses Feb	Clark		professional	•	_			
personal interests spasticity and contracture management (particularly relating to the use of botulinum toxin, medicines, splints and serial casts). No one drug company is ever advocated for pharmacological treatments are discussed generically. I do not privately receive payment for these, my employer receives payment. To the sey and practical fabrication of serial casts. It doesn't advocate for any one intervention over the other, or even over no intervention (as the evidence doesn't promote a stance either way), rather it discusses. Spasticity and titee memb tette memb ership (past and memb ership (past			and	,	since			
interests contracture management (particularly relating to the use of botulinum toxin, medicines, splints and serial casts). No one drug company is ever advocated for — pharmacological treatments are discussed discussed for these, my employer receives payment. The course covers the available evidence base and practical fabrication of serial casts. It doesn't advocate for any one intervention over the other, or even over no intervention (as the evidence doesn't promote a stance either way). rather it discusses reship (past exhip (past and planne and planne d) (Polan treatments are d) d) (Switze (Polan d) d) d) d) d) d) rather it discusses			personal	·	commi			
management (particularly relating to the use of botulinum toxin, medicines, splints and serial casts). No one drug company is ever advocated for — 22 pharmacological treatments are discussed 16- generically, 18/5/2 I do not privately receive payment for these, my employer receives payment. 12/6/2 The course covers the available evidence base and practical fabrication of serial casts. It doesn't advocate for any one intervention over the other, or even over no intervention (as tance desired available evidence doesn't promote a stance either way). rather it discusses memb ership (pat d) (pat and planne d): (polan d) (polan evidence doesn't promote a stance either way). rather it discusses								
(particularly relating to the use of botulinum toxin, medicines, splints and serial casts). No one drug ecompany is ever advocated for 22 pharmacological treatments are discussed 16-generically. I do not privately receive payment for these, my employer receives payment. The course covers the available evidence base and practical fabrication of serial casts. It doesn't advocate for any one intervention (as the evidence doesn't promote a stance either way). rather it discusses file.								
relating to the use of botulinum toxin, and medicines, splints and serial casts). No one drug 8- company is ever 10/04/ advocated for — 22 pharmacological treatments are discussed 16- generically. 18/5/2 I do not privately 2 receive payment for these, my employer receives payment. 12/6/2 The course covers 2 the available evidence base and practical casts. It doesn't advocate for any one intervention of serial casts. It doesn't advocate of average advocate of average advocate of average advocate of average				_				
of botulinum toxin, medicines, splints and serial casts). No one drug 8- company is ever 10/04/ advocated for — 22 pharmacological (Polan treatments are discussed 16- generically. 18/5/2 I do not privately 2 receive payment for these, my rland) employer receives payment. 12/6/2 The course covers the available evidence base and practical casts. It doesn't advocate for any one intervention over the other, or even over no intervention (as the evidence doesn't promote a stance either way). rather it discusses.								
medicines, splints and serial casts). No one drug 8- company is ever 10/04/ advocated for — 22 pharmacological (Polan treatments are d) discussed 16- generically. 18/5/2 I do not privately 2 receive payment (Switze for these, my rland) employer receives payment. 12/6/2 The course covers 2 the available (Polan evidence base and practical fabrication of serial casts. It doesn't 2(UK) advocate for any one intervention (as 4- one intervention (as 2/10/2 the evidence doesn't promote a stance either way). rather it discusses Feb								
and serial casts). No one drug company is ever advocated for — 22 pharmacological treatments are discussed 16- generically. I do not privately receive payment for these, my employer receives payment. 12/6/2 The course covers the available evidence base and practical fabrication of serial casts. It doesn't advocate for any one intervention intervention (as treatments are d) d) control (UK) even over no intervention (as stance either way). rather it discusses d) d) company is ever 10- polan (Folan d) control (Fo				·				
No one drug company is ever advocated for — 22 pharmacological (Polan treatments are d) discussed 16-generically. 18/5/2 I do not privately 2 receive payment (Switze for these, my rland) employer receives 10-payment. 12/6/2 The course covers 2 the available (Polan evidence base and practical casts. It doesn't advocate for any one intervention (as 2/10/2 the evidence a stance either way). rather it discusses Feb				′ '				
company is ever advocated for — 22 pharmacological (Polan treatments are d) discussed 16-generically. 18/5/2 I do not privately 2 receive payment (Switze for these, my rland) employer receives 10-payment. 12/6/2 The course covers 2 the available evidence base and practical 21-fabrication of serial casts. It doesn't 2 (UK) advocate for any one intervention (as the evidence 2 doesn't promote a stance either way). rather it discusses 10/00/2 discusses 10/00/2 (Polan evidence 2 doesn't promote a stance either way). rather it discusses 11/0/2 (Polan evidence 2) doesn't promote a stance either way). rather it discusses Feb				,				
advocated for — pharmacological (Polan treatments are d) discussed 16-generically. 18/5/2 I do not privately 2 receive payment for these, my rland) employer receives 10-payment. 12/6/2 The course covers 2 the available evidence base and practical casts. It doesn't advocate for any one intervention (as the other, or even over no intervention (as stance either way). rather it discusses I do d) had be added to the other of the other way. The course covers are the other way. The course covers are the other way. The course cover the other, or even over no intervention (as stance either way). The course cover over the other way. The course course over the c								
pharmacological treatments are d) discussed 16- generically. 18/5/2 I do not privately 2 receive payment (Switze for these, my rland) employer receives 10- payment. 12/6/2 The course covers 2 (Polan evidence base and practical casts. It doesn't 2(UK) advocate for any one intervention over the other, or even over no intervention (as the evidence a stance either way). rather it discusses I do not privately 2 (Polan evidence (Polan evidence base and d) practical 21- fabrication of serial 22/6/2 casts. It doesn't 2 (UK) advocate for any 4- one intervention 67/22 over the other, or even over no 1- intervention (as 2/10/2 the evidence 2 (Polan stance either way). rather it discusses Feb								
treatments are discussed 16- generically. 18/5/2 I do not privately 2 receive payment (Switze for these, my rland) employer receives 10- payment. 12/6/2 The course covers 2 the available (Polan evidence base and practical casts. It doesn't 2(UK) advocate for any one intervention over the other, or even over no intervention (as the evidence 2 doesn't promote a stance either way). rather it discusses								
discussed generically. I do not privately receive payment for these, my employer receives payment. 12/6/2 The course covers the available evidence base and practical fabrication of serial casts. It doesn't advocate for any one intervention over the other, or even over no intervention (as the evidence doesn't promote a stance either way). rather it discusses I switze (Switze (Switze (Polan (Polan (Polan (Polan (Polan (VE) (Polan (VE) (Polan (VE) (Polan (VE) (Polan (VE) (Polan (Pol					,			
generically. I do not privately receive payment (Switze for these, my rland) employer receives 10-payment. 12/6/2 The course covers 2 (Polan evidence base and practical casts. It doesn't advocate for any one intervention of very even over no intervention (as the evidence doesn't promote a stance either way). rather it discusses I do not privately 2 (Switze rland) and practical 12/6/2 The course covers 2 (Polan evidence labeled and labeled la								
I do not privately receive payment (Switze for these, my rland) employer receives 10-payment. 12/6/2 The course covers the available (Polan evidence base and practical 21-fabrication of serial casts. It doesn't advocate for any one intervention 6/7/22 over the other, or even over no intervention (as 2/10/2 the evidence a stance either way). rather it discusses Feb								
receive payment for these, my employer receives payment. 12/6/2 The course covers the available evidence base and practical fabrication of serial casts. It doesn't advocate for any one intervention intervention (as evidence doesn't promote a stance either way). rather it discusses 10- payment. 12/6/2 The Course covers 2 the available (Polan d) 21- 22/6/2 2 (UK) advocate for any 4- ONE intervention (as 2/10/2 4- COURD COUR								
for these, my employer receives payment. 12/6/2 The course covers the available evidence base and practical casts. It doesn't advocate for any one intervention (as even over no intervention (as tance either way). rather it discusses for these, my rland) rand) rand) rand) rand) rald) ral								
employer receives payment. 12/6/2 The course covers the available (Polan evidence base and practical 21-fabrication of serial casts. It doesn't advocate for any one intervention of even over the other, or even over no intervention (as 2/10/2 the evidence a stance either way). rather it discusses Feb					,			
payment. 12/6/2 The course covers the available (Polan evidence base and practical 21-fabrication of serial casts. It doesn't 2 (UK) advocate for any one intervention 6/7/22 over the other, or even over no intervention (as 2/10/2 the evidence 2 doesn't promote a stance either way). rather it discusses Feb					,			
The course covers the available evidence base and practical 21- fabrication of serial casts. It doesn't advocate for any one intervention over the other, or even over no intervention (as the evidence doesn't promote a stance either way). rather it discusses (Polan (Po								
the available evidence base and practical 21- fabrication of serial casts. It doesn't advocate for any one intervention over the other, or even over no intervention (as intervention (as 2/10/2 the evidence doesn't promote a stance either way). rather it discusses (Polan d)								
evidence base and practical 21- fabrication of serial 22/6/2 casts. It doesn't 2 (UK) advocate for any 4- one intervention 6/7/22 over the other, or even over no intervention (as 2/10/2 the evidence 2 doesn't promote a stance either way). rather it discusses Feb								
practical fabrication of serial casts. It doesn't advocate for any one intervention over the other, or intervention (as the evidence doesn't promote a stance either way). rather it discusses 22/6/2 2 (UK) 4- 0/7/22 0 (UK) 0/7/22 0 (UK) 1- 0/7/22 0 (UK)					,			
fabrication of serial casts. It doesn't 2 (UK) advocate for any one intervention over the other, or even over no intervention (as 2/10/2 the evidence doesn't promote a stance either way). rather it discusses Feb								
casts. It doesn't 2 (UK) advocate for any 4- one intervention 6/7/22 over the other, or (UK) even over no 1- intervention (as 2/10/2 the evidence 2 doesn't promote a stance either way). rather it discusses Feb				'				
advocate for any one intervention over the other, or even over no intervention (as 2/10/2 the evidence doesn't promote a stance either way). rather it discusses Feb								
one intervention over the other, or over the other, or even over no 1-intervention (as 2/10/2 the evidence doesn't promote a stance either way). rather it discusses Feb								
over the other, or (UK) even over no intervention (as 2/10/2 the evidence 2 doesn't promote a (Polan stance either way). rather it discusses Feb				,				
even over no intervention (as 2/10/2 the evidence 2 doesn't promote a (Polan stance either way). d) rather it discusses Feb								
intervention (as 2/10/2 the evidence 2 doesn't promote a stance either way). d) rather it discusses Feb				· ·				
the evidence 2 doesn't promote a (Polan stance either way). d) rather it discusses Feb								
doesn't promote a stance either way). d) rather it discusses Feb				`				
stance either way). d) rather it discusses Feb								
rather it discusses Feb					•			
an individualised 2023								
				an individualised	2023			

			approach to clinical decision making.	(Austr alia) March 2023 (UK)			
Ms Teresa Clark	Committee member	Direct - non- financial professional and personal interests	Receiving training from Merz (botulinum toxin company) to administer xeomin for sialorrhea.	22.07. 2022	20.06.20 22	22.07.2022	
Ms Teresa Clark	Committee member	Direct - non- financial professional and personal interests	I am looking to publish a feasibility paper (currently drafting and approaching journals, early stages) — mixed methods exploring acceptability and feasibility of randomising adults with reduced capacity to consent to RCT research comparing splinting and serial casting following botulinum toxin. Adults with brain injuries.	2022	20.06.20	Ongoing	
Ms Teresa Clark	Committee member	Direct - non- financial professional and personal interests	I am hoping to start a PhD in oct. this will be exploring how we can conduct meaningful research with people with reduced capacity to consent or express their experiences. Methodological and philosophical underpinnings to see if we can move towards useful spasticity/contract ure research design for the	Startin g Octob er 2022	20.06.20	Ongoing	

	T			1	,
		specific health			
		needs of this			
		population.			
Dr Jenny	Committee	ICH/UCL lecture			
Jim	member	09.06.22 MSc Clin			
31111	member	& Applied Paed			
		Neuropsych			
		"Integrated			
		formulations in			
		Paed Neurorehab			
Dr Jenny	Committee	Poster abstract			
Jim	member	accepted for FND			
		Society conference			
		2022 - "Key			
		learning from a			
		pilot			
		multidisciplinary			
		paediatric FND			
		service: the			
		importance of			
		trust, respect and			
		understanding" Jim			
		et al (2022)			
Dr Jenny	Committee	Poster abstract			
Jim	member	accepted for IPBIS			
JIIII	member	·			
		conference 2022 –			
		"The implicit and			
		imperative role of			
		mentalisation in			
		successful staff-			
		parent			
		collaboration in			
		intensive paediatric			
		neurorehabilitation			
		: perspectives from			
		staff" (Peters,			
		Costello, Jim, 2022)			
Dr Jenny	Committee	Paper accepted for			
Jim	member	Neurological			
		Rehabilitation - 'A			
		new model to			
		guide identity-			
		focused			
		multidisciplinary			
		rehabilitation for			
		children & young			
		people following			
		acquired brain			
		injury: I-FoRM'			
		Perkins, Alison;			
		Gracey, F; Kelly,			
1	1	1 11 11	1	1	

Commented [HS1]: Awaiting DOI form to allow for sign off

		Gemma Jenny (:			
Dr Jenny	Committee	Poster	abstract		
Jim	member	accepte	ed for IPBIS		
		confere	ence 2022 -		
		"Hidder	n social		
		inequal	ities in		
		paediat	ric		
		neurore	ehabilitation		
		п			
		(Jim & 0	Costello,		
		2022)			

3. Minutes of last meeting

The Chair asked the committee to confirm the minutes of the last meeting, and the committee confirmed that no changes were required.

4. Morning presentations

Lisa Boardman, Guideline Lead, and Jennifer Francis, Senior Systematic Reviewer, provided an update on matters arising from the action and decision log.

Alice Navein, Systematic Reviewer, presented the 4.5 review question protocol to the committee: 'What is the effectiveness of interventions and approaches for improving and sustaining emotional health and mental wellbeing?'

Ted Barker, Systematic Reviewer, presented the 4.2 review question protocol to the committee: 'What is the effectiveness of interventions and approaches for improving and sustaining physical functioning including strength, mobility and balance'.

5. Afternoon presentations

Ted Barker, Systematic Reviewer continued discussions on the 4.2 review question protocol.

Lisa Boardman, Guideline Lead, led a session for the committee to agree new review questions for key area 4.

Eric Slade, Senior Health Economist, presented the economic plan to the committee.

6. Any other Business

There was no other business to discuss.

The Chair closed the meeting at 16:15

Location and date of next meeting:

Tuesday 5th July 2022 via Zoom